Otonomy, Inc. (Nasdaq: OTIC) today announced the enrollment of the first patient in the single OTIPRIOTM Phase 3 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE